A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma

Journal of the National Cancer Institute

Volumn 101, Issue 3, 2009, Pages 162-175

  Ngan, Elly S W ^a,c   Lang, Brian H H ^a   Liu, Tingting ^a   Shum, Cathy K Y ^a   So, Man Ting ^a   Lau, Danny K C ^a   Leon, Thomas Y Y ^a   Cherny, Stacey S ^a   Tsai, Sophia Y ^b   Lo, Chung Yau ^a   Khoo, Ui Soon ^a   Tam, Paul K H ^a   Garcia Barceló, Maria Mercè ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

STAT3 PROTEIN; THYROID TRANSCRIPTION FACTOR 1; THYROTROPIN;

ANIMAL CELL; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CELL ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE SEQUENCE; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NODULAR GOITER; NONHUMAN; NUCLEOTIDE SEQUENCE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THYROID CARCINOMA; THYROID CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE; ANIMALS; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHILD; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; GOITER, NODULAR; HUMANS; IMMUNOBLOTTING; LUCIFERASES; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID NEOPLASMS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; UP-REGULATION; VALINE; YOUNG ADULT;

EID: 59749093841     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn471     Document Type: Article

References (50)

1. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245(3):366-378.
2. Sherman SI. Thyroid carcinoma. Lancet. 2003;361(9356):501-511.
3. Grossman RF, Tu SH, Duh QY, Siperstein AE, Novosolov F, Clark OH. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. Arch Surg. 1995;130(8):892-897. Discussion 898-899.
4. Uchino S, Noguchi S, Kawamoto H, et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg. 2002;26(8):897-902.
5. Burgess JR, Duffield A, Wilkinson SJ, et al. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J Clin Endocrinol Metab. 1997;82(2):345-348.
6. Musholt TJ, Musholt PB, Petrich T, Oetting G, Knapp WH, Klempnauer J. Familial papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment. World J Surg. 2000;24(11):1409-1417.
7. Arora N, Scognamiglio T, Zhu B, Fahey TJ III. Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg. 2008;32(7):1237-1246.
8. Pucci A, Suppo M, Lucchesi G, et al. Papillary thyroid carcinoma presenting as a solitary soft tissue arm metastasis in an elderly hyperthyroid patient. Case report and review of the literature. Virchows Arch. 2006;448(6):857-861.
9. Bakhsh A, Kirov G, Gregory JW, Williams ED, Ludgate M. A new form of familial multi-nodular goitre with progression to differentiated thyroid cancer. Endocr Relat Cancer. 2006;13(2):475-483.
10. Cavaco BM, Batista PF, Martins C, et al. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocr Relat Cancer. 2008;15(1):207-215.
11. Sturgeon C, Clark OH. Familial nonmedullary thyroid cancer. Thyroid. 2005;15(6):588-593.
12. Guazzi S, Price M, De Felice M, Damante G, Mattei MG, Di Lauro R. Thyroid nuclear factor 1 (TTF-1) contains a homeodomain and displays a novel DNA binding specificity. Embo J. 1990;9(11):3631-3639.
13. DeFelice M, Silberschmidt D, DiLauro R, et al. TTF-1 phosphorylation is required for peripheral lung morphogenesis, perinatal survival, and tissue-specific gene expression. J Biol Chem. 2003;278(37):35574-35583.
14. Civitareale D, Lonigro R, Sinclair AJ, Di Lauro R. A thyroid-specific nuclear protein essential for tissue-specific expression of the thyroglobulin promoter. EMBO J. 1989;8(9):2537-2542.
15. Musti AM, Ursini VM, Avvedimento EV, Zimarino V, Di Lauro R. A cell type specific factor recognizes the rat thyroglobulin promoter. Nucleic Acids Res. 1987;15(20):8149-8166.
16. Francis-Lang H, Price M, Polycarpou-Schwarz M, Di Lauro R. Cell-type-specific expression of the rat thyroperoxidase promoter indicates common mechanisms for thyroid-specific gene expression. Mol Cell Biol. 1992;12(2):576-588.
17. Kikkawa F, Gonzalez FJ, Kimura S. Characterization of a thyroid-specific enhancer located 5.5 kilobase pairs upstream of the human thyroid peroxidase gene. Mol Cell Biol. 1990;10(12):6216-6224.
18. Mizuno K, Gonzalez FJ, Kimura S. Thyroid-specific enhancer-binding protein (T/EBP): cDNA cloning, functional characterization, and structural identity with thyroid transcription factor TTF-1. Mol Cell Biol. 1991;11(10):4927-4933.
19. Civitareale D, Castelli MP, Falasca P, Saiardi A. Thyroid transcription factor 1 activates the promoter of the thyrotropin receptor gene. Mol Endocrinol. 1993;7(12):1589-1595.
20. Kimura S, Hara Y, Pineau T, et al. The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 1996;10(1):60-69.
21. Kusakabe T, Kawaguchi A, Hoshi N, Kawaguchi R, Hoshi S, Kimura S. Thyroid-specific enhancer-binding protein/NKX2.1 is required for the maintenance of ordered architecture and function of the differentiated thyroid. Mol Endocrinol. 2006;20(8):1796-1809.
22. Devriendt K, Vanhole C, Matthijs G, de Zegher F. Deletion of thyroid transcription factor-1 gene in an infant with neonatal thyroid dysfunction and respiratory failure. N Engl J Med. 1998;338(18):1317-1318.
23. Doyle DA, Gonzalez I, Thomas B, Scavina M. Autosomal dominant transmission of congenital hypothyroidism, neonatal respiratory distress, and ataxia caused by a mutation of NKX2-1. J Pediatr. 2004;145(2):190-193.
24. Iwatani N, Mabe H, Devriendt K, Kodama M, Miike T. Deletion of NKX2.1 gene encoding thyroid transcription factor-1 in two siblings with hypothyroidism and respiratory failure. J Pediatr. 2000;137(2):272-276.
25. Moya CM, Perez de Nanclares G, Castano L, et al. Functional study of a novel single deletion in the TITF1/NKX2.1 homeobox gene that produces congenital hypothyroidism and benign chorea but not pulmonary distress. J Clin Endocrinol Metab. 2006;91(5):1832-1841.
26. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res. 1994;54(17):4744-4749.
27. Franceschi S, Preston-Martin S, Dal Maso L, et al. A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control. 1999;10(6):583-595.
28. Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Ultrasound Q. 2006;22(4):231-238. Discussion 239-240.
29. DeLellis R, Lloyd R, Heitz P, Eng C. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. WHO Press; 2004.
30. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol. 2007;14(2):730-738.
31. Garcia-Barcelo M, Ganster RW, Lui VC, et al. TTF-1 and RET promoter SNPs: regulation of RET transcription in Hirschsprung's disease. Hum Mol Genet. 2005;14(2):191-204.
32. Garcia-Barcelo MM, Lau DK, Ngan ES, et al. Evaluation of the NK2 homeobox 1 gene (NKX2-1) as a Hirschsprung's disease locus. Ann Hum Genet. 2008;72(pt 2):170-177.
33. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459-465.
34. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
35. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454-1457.
36. Li C, Zhu NL, Tan RC, Ballard PL, Derynck R, Minoo P. Transforming growth factor-beta inhibits pulmonary surfactant protein B gene transcription through SMAD3 interactions with NKX2.1 and HNF-3 transcription factors. J Biol Chem. 2002;277(41):38399-38408.
37. Ngan ES, Cheng PK, Leung PC, Chow BK. Steroidogenic factor-1 interacts with a gonadotrope-specific element within the first exon of the human gonadotropin-releasing hormone receptor gene to mediate gonadotrope-specific expression. Endocrinology. 1999;140(6):2452-2462.
38. Rios A, Rodriguez JM, Canteras M, Galindo PJ, Balsalobre MD, Parrilla P. Risk factors for malignancy in multinodular goiters. Eur J Surg Oncol. 2004;30(1):58-62.
39. Bottcher Y, Eszlinger M, Tonjes A, Paschke R. The genetics of euthyroid familial goiter. Trends Endocrinol Metab. 2005;16(7):314-319.
40. Moore FD Jr. Inherited aspects of papillary thyroid carcinoma. J Surg Oncol. 2006;94(8):719-724.
41. Lo CY, Chan WF, Lang BH, Lam KY, Wan KY. Papillary microcarcinoma: is there any difference between clinically overt and occult tumors? World J Surg. 2006;30(5):759-766.
42. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell. 1999;98(3):295-303.
43. Kim DW, Chung HK, Park KC, et al. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC). Mol Endocrinol. 2007;21(12):3039-3049.
44. Trovato M, Grosso M, Vitarelli E, et al. Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas. Histol Histopathol. 2003;18(2):393-399.
45. Abubaker J, Jehan Z, Bavi P, et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab. 2008;93(2):611-618.
46. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and PI3K/Akt and MAP kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93(8):3106-3116.
47. Breedveld GJ, van Dongen JW, Danesino C, et al. Mutations in TITF-1 are associated with benign hereditary chorea. Hum Mol Genet. 2002;11(8):971-979.
48. Arnone MI, Zannini M, Di Lauro R. The DNA binding activity and the dimerization ability of the thyroid transcription factor I are redox regulated. J Biol Chem. 1995;270(20):12048-12055.
49. De Felice M, Damante G, Zannini M, Francis-Lang H, Di Lauro R. Redundant domains contribute to the transcriptional activity of the thyroid transcription factor 1. J Biol Chem. 1995;270(44):26649-26656.
50. Zannini M, Acebron A, De Felice M, et al. Mapping and functional role of phosphorylation sites in the thyroid transcription factor-1 (TTF-1). J Biol Chem. 1996;271(4):2249-2254.